Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey guys havent folowed this one in a while. Looks like its built a nice base. Should I be jumping in now? Any recent news? Its down a lot over the years.
but im really looking at another one to make a big move.
That is really good news. Todays pull back was good. Bought a little.
Definitely a pump and dump for now. The deletion was just the reverse split. The price action from Friday would highly suggest another run. Although that doesnt eliminate the chance of a pull back tuesday and then spike a few hours after. Shorts are high from Friday so if hedge funds got in then there should be a spike.
Okay that is good news that the delisting is off the table.
Anythoughts this thing spikes huge monday?
Saw this in the morning and thought to myself doubt volume will pick up at around 11am. Was I completely wrong!!!!
Transgenomic Inc. Announces Collaboration With LifeLabs, Shares Skyrocket 233% On News
What other deals can come following this one with LifeLabs?
woops. Google finance had this in the feed. someone delete it.
So what this is saying 1.5 Million shares locked till Feb 14th?
http://www.streetinsider.com/Corporate+News/MYOS+RENS+Tech+(MYOS)+Discloses+Action+in+Supreme+Court+of+New+York+Against+RENS+Technology+After+Surging+425%25+Intra-Day/12418116.html
You could just hold for the long and maybe hit that 3. Or take these small profits and just buy back at lower. if it keeps running you will have time to catch the rocket. I was lucky to make a little dough on the run up and sold. but gave back some on HSGX.
What was the original reason for that pop to 3 a while back?
A lot of buying in afterhours!
I sold my position yesterday.......damn
Anyone have thoughts on SGNL? Can this run ETRM style?
Whats the float on this thing? Google says ~1million but 20M changing hands?
Any ideas if we have a short squeeze coming? Seems like the huge run up may have had a lot of covering?
Any ideas how far this thing can shoot up? I started to look at this at 13, but didnt notice the low float.
how much on the candle 150k?
ANyone notice that huge pop in August?
etrm can go almost anywhere, 21 should be very possible, after that 25 prob 32. DFFN though looks very interesting. The page does say buyer beware lol. All the shares havent traded several times over. I am debating on buying this one.... would be sweet if it pulled an etrm.
This thing is going to drop real fast.
Provider of high-performance Internet infrastructure services, Internap, Corp. (NASDAQ:INAP), completes initial round of cost cuts and releases initial 2017 financial forecast.
>>>Related articles:
http://www.duncanindependent.com/shares-internap-corp-nasdaqinap-skyrocket-following-completion-initial-round-cost-cuts-initial-2017-forecast/55951/
Wow no comments of late.
I got out early yesterday and was going to get back in by eod but didnt. Missed this run. But this run was hire than the last one to 1.3ish so that is a good sign. Will have to get back in.
What is the current OST?
Eleven Biotherapeutics Inc. (EBIO) reported net income of $19.5 million, or $0.95 per share, during Q3 2016, beating Wall Street loss estimates of $0.17 per share. During the same quarter last year, the company posted a loss of $9.7 million, or $0.50 per share.
Eleven's latest 3Q revenue stood at $28.7 million, compared to $100,0000 in the third quarter of 2015.
The company attributed the latest 3Q swing to profit and spike in revenue to revenue from its license agreement with Roche.
Research and development cost for the Cambridge, Massachusetts-based company came down significantly: from $6.75 million in Q3 2015 to $2.75 million in Q3 2016. However, general and administrative expenses rose from $2.68 million to $6.36 million during the same period, bringing total operating expenses in comparable range: $9.42 million in Q3 2015 versus $9.12 million in Q3 2016.
Eleven Biotherapeutics said the decrease in latest 3Q R&D expenses was due to the discontinuation of development activities for its EBI-005 (isunakinra) and EBI-031 drug candidates.
General and administrative expenses soared due to increased severance, retention and stock-based compensation expenses, professional fees, and its recent acquisition of Viventia Bio Inc. (For more, see Eleven Biotherapeutics Acquires Viventia Bio.)
Eleven Biotherapeutics ended the third quarter with $30.7 million in cash and cash equivalents, which was lower than $36.07 million it had at the end of December 2015. The company believes that its current cash position should fund its operating expenses through 2018.
Corporate Highlights
Eleven Biotherapeutics is a preclinical-stage biopharmaceutical company that discovers and develops protein therapeutics to treat eye diseases.
Major corporate highlights during the recently concluded quarter include an exclusive license agreement Eleven signed with Roche for IL-6 technology, which includes its key drug candidate EBI-031.
It has received $30 million in payments from Roche, and the deal could get Eleven an additional $240 million upon the achievement of certain future regulatory, development and commercialization milestones. In return, Roche gets the exclusive, global license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology.
Eleven also recently completed the acquisition of Viventia Bio Inc., which facilitated it to become a late-stage oncology company.
Eleven Biotherapeutics looks forward to future studies, which includes a Phase III clinical trial of Vicinium for treating bladder cancer, and a Phase II combination trial of Proxinium for squamous cell carcinoma of the head and neck.
As for 2017 plans, Eleven Biotherapeutics CEO Stephen Hurly mentioned, “We plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin.”
Following the quarterly results announcement, Eleven’s stock price soared 11.45%, to close at $2.92 per share on Monday.
Read more: Eleven Biotherapeutics 3Q Net 95c a Share (EBIO) | Investopedia http://www.investopedia.com/news/eleven-biotherapeutics-3q-net-95c-share-ebio/#ixzz4QyH3FS4K
Follow us: Investopedia on Facebook
Was there future payments in the deal as well?
0 Share trades? Did you write that correctly? How is 0 share trades possible?
Stopped following orig and drys for a while. Surprising week from both. Although hasnt DRYS no longer have any shares of ORIG. Also where is DRYS going now? Have we seen the end of this short squeeze? The volume on DRYS picked up a lot early last week. Unbelievable move!
WHat is the current O/S count?
Also have they received any letters from Nasdaq? Where can that be found quickly.
What time of additional payments could be made in the future with the deal and/or what could the profit sharing look like? Does IPCI have anything else in the pipelines?
From what I see in this video is that either one the price was propped up to get some profits for long share holders. or two companies like Apple, Google, and others looked at the balance sheets and decided to pull out.
Or as this former COO says looking at where its trading, it was high, the market heard rumors, may have been a smoke screen to prop up the price...
I think down the road, if not soon, it will be bought out. If this thing hits 14-18. I am sure people familiar with the story will be taking large positions. The sale will come out of no where.
I am long this thing. Sale is coming no idea when.
Agreed. It would take well over 2 years. Apple and rest have been contact Feb. 2016 and they have still yet to have the trial started.
BELLEVUE, Wash., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTCQB:VPLM) is pleased to announce the Company’s patent attorneys, Knobbe Martens Olson & Bear LLP have filed responses this week with the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) on their behalf to the two Petitions for Inter Partes Review (IPR) by Apple. The responses to the petition challenging the RBR ‘815 patent and the petition challenging the RBR Messaging ‘005 patent were filed on Monday, September 19, 2016, and Wednesday, September 21, 2016 respectively. A decision by the PTAB on whether or not to institute the IPR’s is expected in the next 90 days. The IPR responses to the Apple petitions, and the previously filed Unified Patents petition have been posted on the Company’s website voip-pal.com and may be accessed using this link: IPR.
Earlier this year the US Supreme Court affirmed that PTAB decisions whether or not to institute a trial in IPR petitions is “final and non-appealable.”
The IPR petitions were filed in response to Voip-Pal’s combined $7 billion dollar lawsuits against Apple, Verizon and AT&T. The lawsuits have been temporarily postponed by mutual agreement among the parties until the decisions by the PTAB about instituting the reviews, expected before the end of 2016, has been made. The litigation and the IPR’s represent a clear “David and Goliath” fight. Voip-Pal’s current market capitalization is approximately $52 million compared to the combined trillion dollars plus of the defendants: Apple $605 billion, Verizon’s $206 billion, and AT&T’s $244 billion.
CEO, Emil Malak stated, “As with our response to the Unified Patent’s IPR, we invite everyone to read the response to the Apple petitions and draw their own conclusions. While we work diligently to secure the best possible outcome for our shareholders we are reminded during this process as in any legal procedure, patience is a virtue.”
The case seems legit. Plaintiff, Voip-Pal.com, Inc.’s (“VPLM”) Complaint against Defendant Twitter, Inc.,
(“Twitter”), alleges infringement of U.S. Patent No. 8,542,815 (the “‘815 patent”), and its
continuation patent, U.S. Patent No. 9,179,005 (the “‘005 patent”). VPLM further complains and
alleges as follows:.............
But this wont even cost them more then 100Million at best.
The patent is legit, but in no way would they be awarded the figures demanded. This is being used by many companies. 100 Million tops!